ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

ClinicalTrials.gov ID: NCT04136353

Public ClinicalTrials.gov record NCT04136353. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 12:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801): A Randomised Phase 3 Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localised Prostate Cancer

Study identification

NCT ID
NCT04136353
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
University of Sydney
Other
Enrollment
1,100 participants

Conditions and interventions

Interventions

  • Darolutamide Drug
  • External Beam Radiotherapy Radiation
  • Luteinizing Hormone-Releasing Hormone Analog Drug
  • Placebo oral tablet Drug

Drug · Radiation

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 30, 2020
Primary completion
Jan 30, 2028
Completion
Jul 30, 2028
Last update posted
Jul 27, 2023

2020 – 2028

United States locations

U.S. sites
19
U.S. states
7
U.S. cities
18
Facility City State ZIP Site status
Dana-Farber Cancer Institute Boston Massachusetts 02215
Dana Farber Cancer Institute - St. Elizabeth's Brighton Massachusetts 02135
Lahey Hospital and Medical Center Burlington Massachusetts 01805
Dana Farber Cancer Institute - Milford Milford Massachusetts 01757
XCancer Omaha/Urology Cancer Center Omaha Nebraska 68130
Memorial Sloan Kettering Basking Ridge Basking Ridge New Jersey 07920
New Jersey Urology Saddle Brook Clifton New Jersey 07013
Memorial Sloan Kettering Monmouth Middletown New Jersey 07748
Memorial Sloan Kettering Bergen Montvale New Jersey 07645
New Jersey Urology Voorhees Voorhees Township New Jersey 08043
New Mexico Oncology and Hematology Specialists Albuquerque New Mexico 87109
Memorial Sloan Kettering Commack Commack New York 11725
Memorial Sloan Kettering Westchester Harrison New York 10604
New York University Langone Long Island Mineola New York 11501
New York University Langone Medical Center New York New York 10016
Memorial Sloan Kettering Cancer Center New York New York 10065
Memorial Sloan Kettering Nassau Uniondale New York 11553
Dayton Physicians Network Kettering Ohio 45409
Seattle Cancer Care Alliance Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 74 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04136353, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 27, 2023 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04136353 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →